Vivoryon Therapeutics N.V. (AMS:VVY)
Netherlands · Delayed Price · Currency is EUR 1.120
-0.005 (-0.44%)
Aug 14, 2026, 5:35 PM CET
Vivoryon Therapeutics Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | -3.62 | - | 10.76 | |
Revenue Growth | - | - | - | - | - | - |
Cost of Revenue | - | - | - | -0.53 | - | 1.57 |
Gross Profit | - | - | - | -3.1 | - | 9.2 |
Selling, General & Admin | 3.77 | 4.8 | 6.9 | 8.6 | 8.91 | 4.55 |
Research & Development | 3.27 | 4.38 | 14.06 | 17.64 | 20.22 | 17.45 |
Other Operating Expenses | -0.27 | -0.27 | - | -0.5 | -0.02 | -0.01 |
Operating Expenses | 6.78 | 8.91 | 20.96 | 25.74 | 29.11 | 21.99 |
Operating Income | -6.78 | -8.91 | -20.96 | -28.84 | -29.11 | -12.8 |
Interest Expense | -0.04 | -0.05 | -0.05 | -0.06 | -0.02 | -0.02 |
Interest & Investment Income | 0.06 | 0.1 | 0.43 | 0.48 | 0.04 | 0.02 |
Currency Exchange Gain (Loss) | -0 | 0 | 0.02 | -0.2 | 0.69 | 0.75 |
Other Non Operating Income (Expenses) | - | - | - | - | 0.05 | -0.1 |
EBT Excluding Unusual Items | -6.77 | -8.85 | -20.57 | -28.62 | -28.35 | -12.15 |
Gain (Loss) on Sale of Investments | - | - | - | 0.04 | -0.01 | -0.08 |
Gain (Loss) on Sale of Assets | - | - | -0 | - | - | - |
Pretax Income | -6.77 | -8.85 | -20.57 | -28.58 | -28.36 | -12.22 |
Income Tax Expense | - | - | - | -0.23 | -0.2 | 0.43 |
Net Income | -6.77 | -8.85 | -20.57 | -28.34 | -28.16 | -12.66 |
Net Income to Common | -6.77 | -8.85 | -20.57 | -28.34 | -28.16 | -12.66 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 29 | 27 | 26 | 25 | 22 | 20 |
Shares Outstanding (Diluted) | 29 | 27 | 26 | 25 | 22 | 20 |
Shares Change | 10.08% | 3.53% | 3.27% | 14.64% | 10.10% | 0.12% |
EPS (Basic) | -0.24 | -0.33 | -0.79 | -1.12 | -1.28 | -0.63 |
EPS (Diluted) | -0.24 | -0.33 | -0.79 | -1.12 | -1.28 | -0.63 |
EPS Growth | - | - | - | - | - | - |
Free Cash Flow | -7.11 | -8.46 | -19.18 | -21.56 | -21.81 | -11.28 |
Free Cash Flow Per Share | -0.25 | -0.31 | -0.74 | -0.85 | -0.99 | -0.56 |
Gross Margin | - | - | - | - | - | 85.42% |
Operating Margin | - | - | - | - | - | -118.91% |
Profit Margin | - | - | - | - | - | -117.57% |
Free Cash Flow Margin | - | - | - | - | - | -104.77% |
EBITDA | -6.7 | -8.83 | -20.87 | -28.76 | -29.04 | -12.73 |
EBITDA Margin | - | - | - | - | - | -118.22% |
D&A For EBITDA | 0.08 | 0.09 | 0.09 | 0.08 | 0.07 | 0.07 |
EBIT | -6.78 | -8.91 | -20.96 | -28.84 | -29.11 | -12.8 |
EBIT Margin | - | - | - | - | - | -118.91% |